Literature DB >> 24580893

Feasibility of and rectal dosimetry improvement with the use of SpaceOAR® hydrogel for dose-escalated prostate cancer radiotherapy.

Kirsten van Gysen1, Andrew Kneebone, Florencia Alfieri, Linxin Guo, Thomas Eade.   

Abstract

INTRODUCTION: The aim of this study was to investigate the feasibility of injecting a temporary spacer between the rectum and the prostate and to quantify the degree of rectal dosimetric improvement that might result.
METHODS: Ten patients underwent CT and MRI before and after injection of 10 cc of hydrogel and at completion of radiotherapy. Hydrogel was injected under general anaesthetic using a transperineal approach. The primary endpoints were perioperative toxicity and rectal dosimetry (V80, V75, V70, V65, V40 and V30). Secondary endpoints were acute gastrointestinal toxicity during and 3 months following radiotherapy and the stability of the hydrogel. Treatment for all patients was planned incorporating volumetric modulated arc therapy with a D95 of 80 Gy in 40 fractions to the prostate and proximal seminal vesicles on both the pre- and post-hydrogel scans. Toxicity was scored with the Common Terminology Criteria, v. 3.0.
RESULTS: In the first 24 h, two patients described an increase in bowel movement frequency. The comparison plans had identical prescription doses. Rectal doses were significantly lower for all hydrogel patients for all dose endpoints (V80 = 7% vs. 0.1%, V75 = 10.3% vs. 1.1%, V70 = 13.2% vs. 2.7%, V65 = 15.8% vs. 4.6%, V40 = 35.2% vs. 23.3%, V30 = 52.6% vs. 38.5%; P < 0.001). Post-treatment MRI showed gel stability. Grade 1 bowel toxicity was reported in six patients during radiotherapy and two patients at 3 months' follow-up. No Grade 2 or Grade 3 acute bowel toxicity was reported.
CONCLUSION: SpaceOAR hydrogel was successfully injected in 10 patients with minimal side effects. Rectal dosimetry was significantly improved in all patients. This study has been extended to 30 patients with longer follow-up planned.
© 2014 The Royal Australian and New Zealand College of Radiologists.

Entities:  

Keywords:  prostate cancer; radiation therapy; spacer gel; toxicity; treatment planning

Mesh:

Substances:

Year:  2014        PMID: 24580893     DOI: 10.1111/1754-9485.12152

Source DB:  PubMed          Journal:  J Med Imaging Radiat Oncol        ISSN: 1754-9477            Impact factor:   1.735


  15 in total

1.  Rectal ulcer associated with SpaceOAR hydrogel insertion during prostate brachytherapy.

Authors:  Amy Y M Teh; Hung-Ta Ko; Gavin Barr; Henry H Woo
Journal:  BMJ Case Rep       Date:  2014-12-22

2.  The use of hydrogel spacer in men undergoing high-dose prostate cancer radiotherapy: results of a prospective phase 2 clinical trial.

Authors:  Michael Chao; Daryl Lim Joon; Vincent Khoo; Nathan Lawrentschuk; Huong Ho; Sandra Spencer; Yee Chan; Alwin Tan; Trung Pham; Shomik Sengupta; Kevin McMillan; Madalena Liu; George Koufogiannis; Chee Wee Cham; Farshad Foroudi; Damien Bolton
Journal:  World J Urol       Date:  2018-09-24       Impact factor: 4.226

3.  Comparison of rectal dose reduction by a hydrogel spacer among 3D conformal radiotherapy, volumetric-modulated arc therapy, helical tomotherapy, CyberKnife and proton therapy.

Authors:  Masahide Saito; Toshihiro Suzuki; Yuya Sugama; Kan Marino; Naoki Sano; Takafumi Komiyama; Shinichi Aoki; Yoshiyasu Maehata; Kazuya Yoshizawa; Kazunari Ashizawa; Hidekazu Suzuki; Koji Ueda; Yosuke Miyasaka; Masayuki Araya; Hiroshi Takahashi; Hiroshi Onishi
Journal:  J Radiat Res       Date:  2020-05-22       Impact factor: 2.724

4.  Hydrogel spacer shrinkage during external-beam radiation therapy following low-dose-rate brachytherapy for high-risk prostate cancer: a case series.

Authors:  Katsumaro Kubo; Masahiro Kenjo; Hideo Kawabata; Koichi Wadasaki; Mitsuru Kajiwara; Yoshiko Doi; Minoru Nakao; Hideharu Miura; Shuichi Ozawa; Yasushi Nagata
Journal:  J Med Case Rep       Date:  2021-05-26

5.  Ion therapy of prostate cancer: daily rectal dose reduction by application of spacer gel.

Authors:  Antoni Rucinski; Stephan Brons; Daniel Richter; Gregor Habl; Jürgen Debus; Christoph Bert; Thomas Haberer; Oliver Jäkel
Journal:  Radiat Oncol       Date:  2015-02-27       Impact factor: 3.481

6.  A comparison between hydrogel spacer and endorectal balloon: An analysis of intrafraction prostate motion during proton therapy.

Authors:  Samantha G Hedrick; Marcio Fagundes; Ben Robison; Marc Blakey; Jackson Renegar; Mark Artz; Niek Schreuder
Journal:  J Appl Clin Med Phys       Date:  2017-02-25       Impact factor: 2.102

7.  Validation of rectal sparing throughout the course of proton therapy treatment in prostate cancer patients treated with SpaceOAR®.

Authors:  Samantha G Hedrick; Marcio Fagundes; Sara Case; Jackson Renegar; Marc Blakey; Mark Artz; Hao Chen; Ben Robison; Niek Schreuder
Journal:  J Appl Clin Med Phys       Date:  2016-11-30       Impact factor: 2.102

8.  Real-time in vivo dosimetry for SBRT prostate treatment using plastic scintillating dosimetry embedded in a rectal balloon: a case study.

Authors:  Justin L Cantley; Chee-Wai Cheng; Fredrick B Jesseph; Tarun K Podder; Valdir C Colussi; Bryan J Traughber; Lee E Ponsky; Rodney J Ellis
Journal:  J Appl Clin Med Phys       Date:  2016-11-08       Impact factor: 2.102

9.  Prostate motion during radiotherapy of prostate cancer patients with and without application of a hydrogel spacer: a comparative study.

Authors:  Prabhjot Juneja; Andrew Kneebone; Jeremy T Booth; David I Thwaites; Ramandeep Kaur; Emma Colvill; Jin A Ng; Paul J Keall; Thomas Eade
Journal:  Radiat Oncol       Date:  2015-10-24       Impact factor: 3.481

10.  Minimal Rectal Toxicity in the Setting of Comorbid Crohn's Disease Following Prostate Cancer Radiotherapy with a Hydrogel Rectal Spacer.

Authors:  Raj Singh; Philip S Jackson; Mollie Blake; James Cutlip; Sanjeev Sharma
Journal:  Cureus       Date:  2017-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.